Victory Capital Management Inc. lifted its position in Enovis Co. (NYSE:ENOV – Get Rating) by 0.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 416,342 shares of the company's stock after buying an additional 2,360 shares during the period. Victory Capital Management Inc. owned approximately 0.77% of Enovis worth $19,181,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Wipfli Financial Advisors LLC purchased a new stake in Enovis during the 3rd quarter worth approximately $36,000. M&T Bank Corp purchased a new stake in Enovis during the 2nd quarter worth approximately $137,000. Paloma Partners Management Co purchased a new stake in shares of Enovis in the 2nd quarter valued at $209,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Enovis in the 2nd quarter valued at $261,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Enovis in the 2nd quarter valued at $285,000. Hedge funds and other institutional investors own 96.73% of the company's stock.
Get
Enovis alerts:
Analyst Upgrades and Downgrades
Several analysts have recently commented on ENOV shares. Evercore ISI upped their price objective on shares of Enovis to $68.00 in a report on Tuesday, January 3rd. The Goldman Sachs Group initiated coverage on shares of Enovis in a research report on Tuesday, October 11th. They set a "buy" rating and a $57.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Enovis in a report on Wednesday, October 12th. They set a "buy" rating and a $60.00 target price for the company. Robert W. Baird dropped their target price on shares of Enovis from $73.00 to $68.00 and set an "outperform" rating for the company in a report on Thursday, November 3rd. Finally, TheStreet lowered shares of Enovis from a "c" rating to a "d" rating in a report on Wednesday, November 2nd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $63.50.
Insider Transactions at Enovis
In related news, CFO Christopher M. Hix sold 1,367 shares of the business's stock in a transaction dated Wednesday, December 14th. The shares were sold at an average price of $55.28, for a total value of $75,567.76. Following the completion of the transaction, the chief financial officer now owns 44,605 shares of the company's stock, valued at approximately $2,465,764.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at
the SEC website. In other Enovis news, EVP Daniel A. Pryor sold 67,421 shares of Enovis stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $54.58, for a total value of $3,679,838.18. Following the completion of the sale, the executive vice president now owns 75,731 shares in the company, valued at approximately $4,133,397.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
this link. Also, CFO Christopher M. Hix sold 1,367 shares of the business's stock in a transaction dated Wednesday, December 14th. The stock was sold at an average price of $55.28, for a total value of $75,567.76. Following the sale, the chief financial officer now owns 44,605 shares of the company's stock, valued at approximately $2,465,764.40. The disclosure for this sale can be found
here. Corporate insiders own 8.30% of the company's stock.
Enovis Trading Down 0.7 %
ENOV stock opened at $60.54 on Wednesday. The stock has a market cap of $3.28 billion, a P/E ratio of 126.13 and a beta of 1.99. The company's 50 day moving average is $55.55 and its two-hundred day moving average is $53.44. Enovis Co. has a twelve month low of $43.88 and a twelve month high of $129.70.
Enovis (NYSE:ENOV – Get Rating) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.12. Enovis had a net margin of 0.94% and a return on equity of 4.46%. The firm had revenue of $383.81 million for the quarter, compared to analyst estimates of $379.75 million. On average, equities research analysts predict that Enovis Co. will post 2.24 earnings per share for the current year.
Enovis Company Profile
(Get Rating)
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.
Featured Articles
- Get a free copy of the StockNews.com research report on Enovis (ENOV)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- Is It Time To Get Aggressive With Defense Stocks?
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
